Overland Park, KS – In a groundbreaking development, a recent peer-reviewed paper titled “Mesenchymal Stem Cell Extracellular Vesicles from Tissue-Mimetic System Enhance Epidermal Regeneration via Formation of Migratory Cell Sheets,” published on July 29, 2023, in the journal “Tissue Engineering and Regenerative Medicine,” offers open access to its findings. [Read more…]
Revolutionary Study Introduces Advanced Approach to Epidermal Regeneration Using Mesenchymal Stem Cell Secretome and Ronawk’s Bio-Blocks™
Overland Park, KS – A groundbreaking study titled “Tailoring the Secretome Composition of Mesenchymal Stem Cells to Augment Specific Functions of Epidermal Regeneration: An In Vitro Diabetic Model,” conducted by, Jacob G. Hodge, Ph.D., introduces a pioneering strategy to revolutionize epidermal regeneration using the secretome of mesenchymal stem cells (MSCs) utilizing Ronawk’s Bio-Blocks™. Published in June 2023 in the journal
“Frontiers in Medical Technology” and available through open access, the study unveils a powerful solution for optimizing wound healing, particularly in a diabetic context. [Read more…]
Neobiosis Announces FDA Approval of IND for Use of ViXomeTM in COVID-19 ‘Post Covid Syndrome’
GAINESVILLE, Fla., – Neobiosis, is a leading research and manufacturing biotechnology company focused on pioneering the development of novel therapeutics from perinatal tissues as a new class of medicines. Today, Neobiosis announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ViXome™, its drug for the treatment of ‘Post COVID Syndrome (AKA “Long Haul COVID Syndrome”). [Read more…]
Are you looking to accelerate candidates toward commercialization within exosome-based therapeutics?
The 5th Exosomes Based Therapeutic Development Summit is your must-attend meeting with 3 days of carefully curated content from a 30+ world-class speaker faculty. [Read more…]
StemCyte to Supply Raw Materials for Immune Cell Therapies Derived from Umbilical Cord Blood
BALDWIN PARK, Calif., — As international demand for starting substances for use in cell therapy emerges, California-based regenerative therapeutics company StemCyte announced it has signed a cooperation agreement with a leading US cell therapy company that is developing allogeneic genetically modified CAR-NK cells using umbilical cord blood. StemCyte has agreed to supply the necessary cellular raw materials for allogeneic cell therapy product development worldwide. [Read more…]
- « Previous Page
- 1
- …
- 120
- 121
- 122
- 123
- 124
- …
- 338
- Next Page »